Indication
Hypomethylating agent
1 clinical trial
2 products
Clinical trial
A Single Arm, Phase 2 Study Evaluating Safety and Efficacy of Maintenance Therapy With Hypomethylating Agent and Venetoclax After Allogeneic Stem Cell Transplantation in Patients With f High-risk Myeloid Malignancies.Status: Recruiting, Estimated PCD: 2024-12-31
Product
VenetoclaxProduct
Azacitidine